Anti‐monkeypox virus‐neutralizing activities of human immunoglobulin manufactured between 1999 and 2021 and derived from donors in the United States and Japan-Reference-Cited by-同舟云学术

Anti‐monkeypox virus‐neutralizing activities of human immunoglobulin manufactured between 1999 and 2021 and derived from donors in the United States and Japan

Published:2024-05-13 Issue:8 Volume:119 Page:878-882
ISSN:0042-9007
Container-title:Vox Sanguinis
language:en
Short-container-title:Vox Sanguinis

Author:

Yunoki Mikihiro¹²^ORCID,Kubota‐Koketsu Ritsuko²,Shioda Tatsuo²

Affiliation:

1. Research and Development Division Japan Blood Products Organization Tokyo Japan

2. Department of Viral Infections Research Institute for Microbial Diseases, Osaka University Suita Osaka Japan

Abstract

AbstractBackground and ObjectivesIn May 2022, the United Kingdom reported the first case of chained transmission of the monkeypox (mpox) virus without any known epidemiological links to west or central Africa. The monthly number of mpox patients currently has passed a peak and is declining globally, and infected patients include both non‐vaccinated and vaccinated individuals. Herein, the virus‐neutralizing (VN) activity against vaccinia viruses, which are considered to cross‐react with the mpox virus, in the intravenous immunoglobulin (IVIG) lots derived from donors, including vaccinated Japanese populations, was evaluated to clarify the status of the Japanese blood donor population.Materials and MethodsVN titres against vaccinia and human mpox viruses in IVIG lots derived from donors in Japan and the United States manufactured between 1999 and 2021 and 1995 and 2001, respectively, were evaluated by neutralization testing.ResultsVN titres of IVIG derived from donors in Japan and the United States against vaccinia and mpox viruses showed a slowly decreasing trend between 1999 and 2021.ConclusionVN titres are expected to decrease in the future since the percentage of vaccinated donors in the donor population seems to have decreased. Therefore, continuous monitoring of VN titres is required.

Funder

Japan Blood Products Organization

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/vox.13655

Reference14 articles.

1. WHO.History of the smallpox vaccine.https://www.who.int/news‐room/spotlight/history‐of‐vaccination/history‐of‐smallpox‐vaccination?topicsurvey=ht7j2q)&gclid=EAIaIQobChMIhquputyAgQMV4M8WBR0pFw‐tEAAYASABEgLQifD_BwE. Last accessed 29 Aug 2023.

2. Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations;Hatakeyama S;Clin Diagn Lab Immunol,2005

3. Status of smallpox antibody retention 28 years after the abolition of smallpox vaccine;Takeuchi Y;Modern Media,2006

4. Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia

5. European Centre for Disease Prevention and Control.Monkeypox multi‐country outbreak.2022.https://www.ecdc.europa.eu/sites/default/files/documents/Monkeypox‐multi‐country‐outbreak.pdf. Last accessed 7 Jul 2023.